Abstract
Whole-breast external beam radiotherapy (WB-EBRT) is the standard of care in the UK among patients with early invasive breast cancer (BC) following breast-conserving surgery but is associated with short- and long-term adverse effects. The INTRABEAM® device may be used to deliver adjuvant targeted intraoperative radiation therapy (TARGIT-IORT) to patients with early BC at the time of surgery, while reducing treatment-associated burden, resource utilization, and exposure to radiation and relevant toxicities. An economic evaluation was performed to assess the cost-effectiveness of INTRABEAM over a lifetime horizon, from a UK National Health Service (NHS) perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
